Status Covid & Flu Antigen Test
Tests for Covid-19, Flu A, Flu B
Results in 20 minutes
Nasopharyngeal swab
Covid: 93.9% PPA, 100.0% NPA
Flu A: 91.4% PPA, 95.7% NPA
Flu B: 87.6% PPA, 95.9% NPA
Tests for Covid-19, Flu A, Flu B
Results in 20 minutes
Nasopharyngeal swab
Covid: 93.9% PPA, 100.0% NPA
Flu A: 91.4% PPA, 95.7% NPA
Flu B: 87.6% PPA, 95.9% NPA
Tests for Covid-19, Flu A, Flu B
Results in 20 minutes
Nasopharyngeal swab
Covid: 93.9% PPA, 100.0% NPA
Flu A: 91.4% PPA, 95.7% NPA
Flu B: 87.6% PPA, 95.9% NPA
Specifications
CLIA Waived
Test type: Rapid Antigen
Run time: 20 minutes
Collection type: Nasopharyngeal/lower nasal swab
SARS-CoV-2: 93.9% PPA, 100.0% NPA
Flu A: 91.4% PPA, 95.7% NPA
Flu B: 87.6% PPA, 95.9% NPA
CPT Codes: Covid-19 87811QW
Manufacturer: Princeton BioMeditech (USA)
Storage & Expiration
Store at 2-30°C (35-86°F)
Do not freeze any contents of the kit.
Reagents and materials are stable until expiration date printed on outer packaging.
Test device must remain in the sealed pouch until use.
Box Components
Nasopharyngeal swabs (25)
Test cassettes (25)
Extraction reagent capsules (25)
Workstation for mass testing (1)
Instructions for use (1)
Manuals & Documents
Intended Use
Status COVID-19/Flu test is a lateral flow immunoassay intended for the in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV2, influenza A and influenza B directly from nasopharyngeal swab specimens obtained from individuals, who are suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider, within the first five days of onset of symptoms. Clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2 and influenza can be similar. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high, or waived complexity tests. This test is authorized for use in professional settings operating under a CLIA license.